Literature DB >> 21277930

Comparisons of methamphetamine psychotic and schizophrenic symptoms: a differential item functioning analysis.

Manit Srisurapanont1, Suwanna Arunpongpaisal, Kiyoshi Wada, John Marsden, Robert Ali, Ronnachai Kongsakon.   

Abstract

The concept of negative symptoms in methamphetamine (MA) psychosis (e.g., poverty of speech, flatten affect, and loss of drive) is still uncertain. This study aimed to use differential item functioning (DIF) statistical techniques to differentiate the severity of psychotic symptoms between MA psychotic and schizophrenic patients. Data of MA psychotic and schizophrenic patients were those of the participants in the WHO Multi-Site Project on Methamphetamine-Induced Psychosis (or WHO-MAIP study) and the Risperidone Long-Acting Injection in Thai Schizophrenic Patients (or RLAI-Thai study), respectively. To confirm the unidimensionality of psychotic syndromes, we applied the exploratory and confirmatory factor analyses (EFA and CFA) on the eight items of Manchester scale. We conducted the DIF analysis of psychotic symptoms observed in both groups by using nonparametric kernel-smoothing techniques of item response theory. A DIF composite index of 0.30 or greater indicated the difference of symptom severity. The analyses included the data of 168 MA psychotic participants and the baseline data of 169 schizophrenic patients. For both data sets, the EFA and CFA suggested a three-factor model of the psychotic symptoms, including negative syndrome (poverty of speech, psychomotor retardation and flatten/incongruous affect), positive syndrome (delusions, hallucinations and incoherent speech) and anxiety/depression syndrome (anxiety and depression). The DIF composite indexes comparing the severity differences of all eight psychotic symptoms were lower than 0.3. The results suggest that, at the same level of syndrome severity (i.e., negative, positive, and anxiety/depression syndromes), the severity of psychotic symptoms, including the negative ones, observed in MA psychotic and schizophrenic patients are almost the same.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21277930     DOI: 10.1016/j.pnpbp.2011.01.014

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  20 in total

1.  Addiction potential of phentermine prescribed during long-term treatment of obesity.

Authors:  E J Hendricks; M Srisurapanont; S L Schmidt; M Haggard; S Souter; C L Mitchell; D G De Marco; M J Hendricks; Y Istratiy; F L Greenway
Journal:  Int J Obes (Lond)       Date:  2013-05-17       Impact factor: 5.095

2.  Serotonin in the ventral hippocampus modulates anxiety-like behavior during amphetamine withdrawal.

Authors:  W Tu; A Cook; J L Scholl; M Mears; M J Watt; K J Renner; G L Forster
Journal:  Neuroscience       Date:  2014-09-18       Impact factor: 3.590

3.  Unusual effects of nicotine as a psychostimulant on ambulatory activity in mice.

Authors:  Toyoshi Umezu
Journal:  ISRN Pharmacol       Date:  2012-03-20

4.  Differential patterns of blood oxygenation in the prefrontal cortex between patients with methamphetamine-induced psychosis and schizophrenia.

Authors:  Kazuhiko Yamamuro; Manabu Makinodan; Sohei Kimoto; Naoko Kishimoto; Tsubasa Morimoto; Michihiro Toritsuka; Kiwamu Matsuoka; Yoshihiro Takebayashi; Tomoyo Takata; Masato Takahashi; Yoshinori Tanimura; Yosuke Nishihata; Yasuhiro Matsuda; Toyosaku Ota; Hiroki Yoshino; Junzo Iida; Toshifumi Kishimoto
Journal:  Sci Rep       Date:  2015-07-16       Impact factor: 4.379

5.  Clinical features, course and treatment of methamphetamine-induced psychosis in psychiatric inpatients.

Authors:  Homa Zarrabi; Mohammadrasoul Khalkhali; Azam Hamidi; Reza Ahmadi; Maryam Zavarmousavi
Journal:  BMC Psychiatry       Date:  2016-02-25       Impact factor: 3.630

6.  Candidate gene networks and blood biomarkers of methamphetamine-associated psychosis: an integrative RNA-sequencing report.

Authors:  M S Breen; A Uhlmann; C M Nday; S J Glatt; M Mitt; A Metsalpu; D J Stein; N Illing
Journal:  Transl Psychiatry       Date:  2016-05-10       Impact factor: 6.222

7.  Psychosis associated with acute recreational drug toxicity: a European case series.

Authors:  Odd Martin Vallersnes; Alison M Dines; David M Wood; Christopher Yates; Fridtjof Heyerdahl; Knut Erik Hovda; Isabelle Giraudon; Paul I Dargan
Journal:  BMC Psychiatry       Date:  2016-08-18       Impact factor: 3.630

8.  Domestic Violence in Methamphetamine Psychotic Users, Psychiatric Inpatients, and Healthy People: A Comparative Study.

Authors:  Seyed Mohammad Rasoul Khalkhali; Kiomars Najafi; Reza Ahmadi; Azadeh Yousefnezhad; Azam Hamidi; Masoumeh Ellahi; Ali Amiri; Afsar Montakhabi; Maryam Zavarmousavi
Journal:  Iran J Med Sci       Date:  2016-11

Review 9.  Amphetamine-induced psychosis--a separate diagnostic entity or primary psychosis triggered in the vulnerable?

Authors:  Jørgen G Bramness; Øystein Hoel Gundersen; Joar Guterstam; Eline Borger Rognli; Maija Konstenius; Else-Marie Løberg; Sigrid Medhus; Lars Tanum; Johan Franck
Journal:  BMC Psychiatry       Date:  2012-12-05       Impact factor: 3.630

Review 10.  The neurobiology of methamphetamine induced psychosis.

Authors:  Jennifer H Hsieh; Dan J Stein; Fleur M Howells
Journal:  Front Hum Neurosci       Date:  2014-07-22       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.